Curatis: Sales growth of 30% in distribution - plus significant expansion of patient target group for lead project C-PTBE-01
Curatis Holding AG (SIX:CURN, ‘Curatis’) reports business revenues of CHF 6.9m for 2024, whereby Curatis AG is only included for 8 months. Curatis AG was able to increase sales in the distribution business by 30% per cent to CHF 9.5m in the full year 2024 compared to 2023.
Further key statements:
- Curatis is increasing the estimate for the number of patients addressed in the lead project C-PTBE-01 by a factor of 20.
- The reason for this is that Curatis can apply for a biologics licence for C-PTBE-01, which grants 12 years of market protection in the USA. This suggests an expansion of the indications, namely from PTBE in diffuse midline glioma (DMG) in children to PTBE in other primary and metastatic brain tumours in children and adults.
- A meeting with the US Food and Drug Administration (FDA) to discuss a potential pivotal Phase III trial for C-PTBE-01 is in preparation and is targeted for Q2.
- The strong cash position of CHF 3m at the end of the year combined with the positive, growing cash flow from sales and the lean organisation provide a solid foundation for Curatis' operating activities.
Business Development and finances
Product revenue in 2024 amounted to CHF 6.4m and service revenue to CHF 0.5m, whereby Curatis AG, which was acquired on 26 April 2024, is only included in this figure for 8 months. On a full year basis, Curatis AG was able to increase sales in its distribution business from CHF 7.3m (2023) to CHF 9.5m (2024), which corresponds to growth of 30%. This strong growth is due to significant organic growth as well as newly launched products. It is in line with Curatis' strategy to support products in the registration phase in order to subsequently assume responsibility for distribution, as well as to take over already launched products from competitors. The operating loss for the period amounted to CHF 3.3m and includes several non-cash-relevant special effects such as personnel costs due to the revaluation of the option plan that Curatis AG has operated since 2015 (CHF 2.5m). In addition, one-off costs were incurred in relation to the transaction in April 2024 (approx. CHF 1.3m).
The strong cash position of Curatis as at 31 December 2024 of CHF 3.0m combined with a positive cash flow from the operating business of Curatis AG (excluding transaction costs and development costs) and the lean structure secure the operating activities of Curatis.
In CHFm | 31. December 2024 | 31. December 2023 |
Revenues | 6.9 | 0 |
Operating Result | (3.3) | (16.3) |
Thereof non-cash | (2.5) | (12.4) |
Thereof transaction costs | (1.3) | 0 |
Cash and cash equivalents | 3.0 | 0 |
Lead project C-PTBE-01: Significantly more addressable patients
On 14 November 2024, Curatis announced that the approval of the lead project C-PTBE-01 will be sought via the Biologic License Application (BLA) route. While the path of the Phase III study and approval with a focus on children is not expected to change, the development of C-PTBE-01 will no longer focus solely on PTBE in children with Diffuse Midline Glioma (DMG). The expanded target population will now include children and adults with PTBE in primary and metastatic brain tumours. Curatis is evaluating conducting a study in adult patients with PTBE shortly after the paediatric study.
Curatis is therefore increasing the estimate of the addressable patient pool from less than 1,000 patients (PTBE in children with DMG only) in the US today to approximately 20 times the number of patients in the US (children in other indications as well as adults). The same applies to regions outside the USA.
Outlook for 2025: Stable sales and earnings growth and progress expected with C-PTBE-01
The first months of 2025 were in line with the budget. Curatis is confident that it will be able to further increase sales in 2025.
CMC development activities (active pharmaceutical ingredient and drug product) for C-PTBE-01 are proceeding according to plan. A first batch of the active ingredient has now been produced. A meeting with the US Food and Drug Administration (FDA) to discuss a possible pivotal Phase III trial for C-PTBE-01 is in preparation. The meeting with the FDA is planned for Q2 2025. Initial discussions are also taking place in the area of partnering and will be intensified after the meeting with the FDA.
For a more detailed discussion of the figures, please refer to the annual report and the associated management report, which are available on the Curatis website at www.curatis.com.
There will be no presentation on the annual figures, but the company will be available to answer questions. The Annual General Meeting will take place on 23 May 2025 at 2.30 pm in Pratteln.
More detailed information on C-PBTE-01
Peritumoural brain edema is associated with many primary and metastatic brain tumours, leading to indirect impairment of brain function due to accumulation of extracellular fluid around the tumour. Peritumoural brain edema can cause symptoms such as headaches, vomiting and neurological dysfunctions such as paralysis, speech disorders, visual problems and altered mental status. They can be life-threatening.
The standard treatment for PTBE is the use of corticosteroids. These often have serious side effects such as severe myopathy, muscle wasting, abnormal weight gain, osteoporosis, gastritis, gastrointestinal bleeding, hypertension and personality changes. C-PTBE-01 has shown a strong steroid-sparing effect in two clinical safety and efficacy studies, which can lead to a significant reduction or complete replacement of steroid use. This can alleviate the severe steroid-induced side effects and thus improve the quality of life of those affected.
About Curatis:
Curatis Holding AG is a publicly listed company (CURN.SW) specialising in the development and commercialisation of drugs for rare and very rare diseases. Curatis has a portfolio of more than 40 marketed products and a pipeline of orphan and specialty products. More information can be found on the website www.curatis.com.
Disclaimer:
The information contained in this media release and in any link to our website indicated herein is not for use within any country or jurisdiction or by any persons where such use would constitute a violation of law. If this applies to you, you are not authorized to access or use any such information.
This media release contains “forward-looking statements” that are based on our current expectations, assumptions, estimates and projections about us and our industry. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain the words “may”, “will”, “should”, “continue”, “believe”, “anticipate”, “expect”, “estimate”, “intend”, “project”, “plan”, “will likely continue”, “will likely result”, or words or phrases with similar meaning. Undue reliance should not be placed on such statements because, by their nature, forward-looking statements involve risks and uncertainties, including, without limitation, economic, competitive, governmental and technological factors outside of the control of Curatis Group, that may cause Curatis’ business, strategy or actual results to differ materially from the forward-looking statements (or from past results). For any factors that could cause actual results to differ materially from the forward-looking statements contained in this media release, please see the risk factors included in our listing prospectus in connection with the Business Combination. Curatis Group undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise. It should further be noted that past performance is not a guide to future performance. Persons requiring advice should consult an independent adviser.
The information contained in this media release is not an offer to sell or a solicitation of offers to purchase or subscribe for securities. This media release is not a prospectus within the meaning of the Swiss Financial Services Act nor a prospectus under any other applicable laws.
Some financial information in this media release has been rounded and, as a result, the figures shown as totals in this media release may vary slightly from the exact arithmetic aggregation of the figures that precede them.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326494260/en/
Contacts
Patrick Ramsauer
CFO Curatis
Phone: +41 61 927 8777
ir@curatis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Partners with Barclays on Global Treasury Management with Proprietary AI-Powered FX Model9.5.2025 16:57:00 EEST | Press release
Ant International has entered a partnership with leading UK bank Barclays to enhance efficiency and resilience in global treasury management for businesses. Under the partnership, the two sides will combine innovative solutions, including Ant’s proprietary Time-Series Transformer (TST) AI FX Model, to help businesses reduce FX-related costs and risks against global volatilities. At the initial stage of the collaboration, Ant International has successfully completed the first batch of its intra-group FX transactions with Barclays. Ant International’s TST Model is a transformer architecture-based big data model with close to 2 billion parameters. By integrating the latest time series forecasting algorithms, the TST Model predicts patterns over time. Ant also created new pre-training and Supervised Fine-Tuning (SFT) frameworks to train the model and improve its predictions over time. The TST Model now forecasts the company's cashflow and FX exposure on an hourly, daily and weekly basis, w
Monument Re Transfers €1.4bn Greycastle Portfolio to RGA and Strengthens European Life Insurance Consolidation Platform9.5.2025 15:00:00 EEST | Press release
Monument Re Limited (“Monument”) announces today that it has transferred a legacy €1.4bn reinsurance portfolio, comprising annuity and other life insurance liabilities acquired as part of the 2020 Greycastle transaction, to RGA Americas Reinsurance Company, Ltd. (“RGA”). This transaction releases capital resources that Monument will redirect to its core strategy of consolidation in European life insurance markets. The transaction completed on 2May 2025 following approval by the Boards of Directors of both Monument and RGA and non-objection from the Bermuda Monetary Authority. Monument has taken significant steps in recent months to strengthen its business operations by consolidating its European group support functions in Dublin and by aligning with the recently strengthened regulatory regime in Bermuda. With its strong financial position and best in class capabilities in the Group, Monument remains ideally positioned to build on its success to date and grow its European footprint, del
IFF Completes Divestiture of Nitrocellulose Business9.5.2025 15:00:00 EEST | Press release
IFF (NYSE: IFF) today announced that it has completed the divestiture of its nitrocellulose business, including Walsrode Industrial Park in lower Saxony, Germany, to Czechoslovak Group (CSG). The business manufactures nitrocellulose strictly for industrial purposes, serving customers primarily in coatings and printing inks, and had been part of IFF’s Pharma Solutions business unit. “The divestiture of our nitrocellulose business builds upon our deleveraging journey and enables us to focus on our core businesses,” said Erik Fyrwald, IFF CEO. “I’d like to thank our nitrocellulose colleagues for their dedication and wish them continued success as part of CSG.” Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Le
CPAC Systems AB Announces Strategic Minority Investment in Flying Fish9.5.2025 13:33:00 EEST | Press release
CPAC Systems AB, a leader in advanced control systems and embedded vessel and commercial vehicle technology, today announced a strategic minority investment in Flying Fish Maritime Innovations B.V., a pioneer in advanced shared water mobility solutions and robust, cost-effective hydrofoil technology. The investment underscores both companies’ commitment to redefining water-based transportation through innovation, sustainability, and seamless integration. It marks the beginning of a deeper collaboration aimed at enabling smarter, cleaner, and more connected mobility on the water — for both recreational and commercial applications. “We are thrilled to support Flying Fish and their impressive work in redefining water mobility,"saidMarcus Wingolf, CEO of CPAC Systems. "Our investment in Flying Fish represents a strategic alignment of our technical proficiencies and innovative ambitions. This partnership opens exciting new possibilities for integration and sustainable transformation across
Kioxia Receives IEEE Corporate Innovation Award9.5.2025 10:00:00 EEST | Press release
Kioxia Corporation, a world leader in memory solutions, today announced that it has received the IEEE Corporate Innovation Award from the Institute of Electrical & Electronics Engineers (IEEE), the world’s largest technical professional organization dedicated to advancing technology for the benefit of humanity. This award recognizes Kioxia's outstanding contribution in the field of electrical and electronics engineering through its BiCS FLASH™ technology, a low-cost, high-capacity 3D flash memory innovation. The award ceremony was held on April 24 in Tokyo. The IEEE Corporate Innovation Award is a globally-recognized honor bestowed upon organizations that have developed innovative technologies, products or services that have made a substantial contribution to the advancement of electrical and electronics engineering. Since its inception in 1985, the award has been presented to leading electronics manufacturers and IT companies worldwide, and Kioxia is proud to be the seventh Japanese c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom